Q2 2024 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2024-08-14 · accession 0001104659-24-089629
$7.56B
Reported value
78
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $1.38B | 18.2% | 10,108,400 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $619.5M | 8.19% | 8,203,754 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $383.9M | 5.08% | 9,165,652 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $332.5M | 4.40% | 7,506,934 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $249.8M | 3.30% | 6,084,412 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $227.7M | 3.01% | 982,139 | Common | SOLE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $223.4M | 2.95% | 31,419,267 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT INC | $222.3M | 2.94% | 3,694,825 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $220.6M | 2.92% | 5,400,408 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $213.5M | 2.82% | 6,049,204 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $195.9M | 2.59% | 46,202,425 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $170.6M | 2.26% | 10,689,545 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $166.6M | 2.20% | 10,416,609 | Common | SOLE |
| 30050B101 | EVH | EVOLENT HEALTH INC - A | $162.8M | 2.15% | 8,514,862 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $160.5M | 2.12% | 8,909,091 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $154.9M | 2.05% | 8,064,000 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS-A | $115.4M | 1.53% | 15,384,615 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $113.5M | 1.50% | 14,175,398 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC - ADR | $110.4M | 1.46% | 7,632,646 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $108.5M | 1.43% | 7,871,721 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $107.0M | 1.42% | 5,098,211 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $92.4M | 1.22% | 10,860,977 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $90.8M | 1.20% | 18,202,009 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $88.9M | 1.18% | 3,289,119 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $88.5M | 1.17% | 1,604,014 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $80.5M | 1.06% | 1,000,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $77.2M | 1.02% | 1,961,863 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $77.0M | 1.02% | 6,601,689 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $74.5M | 0.99% | 1,896,772 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $72.3M | 0.96% | 4,178,823 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $72.0M | 0.95% | 11,609,704 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $63.9M | 0.84% | 10,805,129 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $60.4M | 0.80% | 2,333,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $56.8M | 0.75% | 4,850,984 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $52.2M | 0.69% | 3,517,259 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $51.7M | 0.68% | 3,083,430 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $51.1M | 0.68% | 1,235,599 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $49.6M | 0.66% | 2,122,465 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $48.4M | 0.64% | 8,340,508 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $45.9M | 0.61% | 5,043,756 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC-ADR | $45.6M | 0.60% | 2,253,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $44.1M | 0.58% | 1,397,433 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $43.8M | 0.58% | 6,045,351 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $36.1M | 0.48% | 14,932,063 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $32.7M | 0.43% | 2,538,925 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $26.4M | 0.35% | 2,033,056 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $24.6M | 0.32% | 4,330,446 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $24.4M | 0.32% | 10,872,503 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $23.6M | 0.31% | 7,622,347 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $22.7M | 0.30% | 22,748,880 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $22.5M | 0.30% | 4,878,000 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $22.3M | 0.29% | 2,085,554 | Common | SOLE |
| N44445109 | IMTX | IMMATICS NV | $20.3M | 0.27% | 1,750,000 | Common | SOLE |
| 81749D107 | SERA | SERA PROGNOSTICS INC-A | $18.0M | 0.24% | 3,032,808 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $15.3M | 0.20% | 9,192,092 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $15.0M | 0.20% | 6,144,881 | Common | SOLE |
| 15713L109 | CRVO | CERVOMED INC | $14.0M | 0.19% | 817,120 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $13.8M | 0.18% | 1,281,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $13.6M | 0.18% | 650,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $13.4M | 0.18% | 200,000 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $11.9M | 0.16% | 5,551,295 | Common | SOLE |
| 23256X100 | — | CYBIN INC | $11.9M | 0.16% | 44,004,464 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $11.3M | 0.15% | 3,217,503 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $11.2M | 0.15% | 421,348 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $11.2M | 0.15% | 6,250,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $10.8M | 0.14% | 672,712 | Common | SOLE |
| 007002108 | TORCEUR | ADICET BIO INC | $9.1M | 0.12% | 7,541,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC-A | $9.1M | 0.12% | 119,789 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $8.8M | 0.12% | 2,082,021 | Common | SOLE |
| 10170A100 | BOLD | BOUNDLESS BIO INC | $8.4M | 0.11% | 2,180,631 | Common | SOLE |
| 16934W106 | CMRXEUR | CHIMERIX INC | $7.7M | 0.10% | 8,800,000 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAPITAL SOLUTIONS | $7.5M | 0.10% | 750,000 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $6.0M | 0.08% | 1,477,749 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTIC INC | $4.0M | 0.05% | 1,900,000 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $3.1M | 0.04% | 282,580 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA CO NV-27 | $2.9M | 0.04% | 333,333 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $1.3M | 0.02% | 2,632,200 | Common | SOLE |
| 80880W106 | SCLXUSD | SCILEX HOLDING CO | $504,075 | 0.01% | 261,179 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.